V600 mutations in BRAF, which activate the MAPK pathway, have been identified in 5–15% of cases of low-grade gliomas but are less frequent in high-grade gliomas, such as glioblastomas (approximately 3%).4 The gene discussed is BRAF; the disease is central nervous system cancer.